Evidence map›Paper›PMID 24795811›Full record

ReviewBoneKEy reports2014

Fracture healing and lipid mediators.

J Patrick O'Connor, Michaele B Manigrasso, Brian D Kim, Sangeeta Subramanian

Abstract readReview
In one paragraph

Review in BoneKEy reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. COX-2 in Fracture Callus Chondro-Osseous Junction Osteoclasts Regulates Chondrocyte Hypertrophy and Callus Vasculogenesis.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025
    Article
  4. Article
  5. Lipolysis products from triglyceride-rich lipoproteins induce stress protein ATF3 in osteoblasts.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J Patrick O'ConnorDepartment of Biochemistry & Molecular Biology, New Jersey Medical School and Graduate School of Biomedical Sciences, Rutgers, the State University of New Jersey , Newark, NJ, USA.
Michaele B ManigrassoDepartment of Biochemistry & Molecular Biology, New Jersey Medical School and Graduate School of Biomedical Sciences, Rutgers, the State University of New Jersey , Newark, NJ, USA.
Brian D KimDepartment of Biochemistry & Molecular Biology, New Jersey Medical School and Graduate School of Biomedical Sciences, Rutgers, the State University of New Jersey , Newark, NJ, USA.
Sangeeta SubramanianDepartment of Biochemistry & Molecular Biology, New Jersey Medical School and Graduate School of Biomedical Sciences, Rutgers, the State University of New Jersey , Newark, NJ, USA.
Rutgers, The State University of New Jersey · US

Funding

Local Modulation of Inflammation to Heal Cranial-facial Bone DefectsR01DE019926 · NIDCR · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI O'CONNOR, J PATRICK, RICCI, JOHN · 2009 to 2012
$2.5M
NIDCR NIH HHS R01 DE019926
6 · The paper itself

Abstract

Lipid mediators regulate bone regeneration during fracture healing. Prostaglandins and leukotrienes are well-known lipid mediators that regulate inflammation and are synthesized from the Ω-6 fatty acid, arachidonic acid. Cyclooxygenase (COX-1 or COX-2) and 5-lipoxygenase (5-LO) catalyze the initial enzymatic steps in the synthesis of prostaglandins and leukotrienes, respectively. Inhibition or genetic ablation of COX-2 activity impairs fracture healing in animal models. Genetic ablation of COX-1 does not affect the fracture callus strength in mice, suggesting that COX-2 activity is primarily responsible for regulating fracture healing. Inhibition of cyclooxygenase activity with nonsteroidal anti-inflammatory drugs (NSAIDs) is performed clinically to reduce heterotopic ossification, although clinical evidence that NSAID treatment impairs fracture healing remains controversial. In contrast, inhibition or genetic ablation of 5-LO activity accelerates fracture healing in animal models. Even though prostaglandins and leukotrienes regulate inflammation, loss of COX-2 or 5-LO activity appears to primarily affect chondrogenesis during fracture healing. Prostaglandin or prostaglandin analog treatment, prostaglandin-specific synthase inhibition and prostaglandin or leukotriene receptor antagonism also affect callus chondrogenesis. Unlike the Ω-6-derived lipid mediators, lipid mediators derived from Ω-3 fatty acids, such as resolvin E1 (RvE1), have anti-inflammatory activity. In vivo, RvE1 can inhibit osteoclastogenesis and limit bone resorption. Although Ω-6 and Ω-3 lipid mediators have clear-cut effects on inflammation, the role of these lipid mediators in bone regeneration is more complex, with apparent effects on callus chondrogenesis and bone remodeling.

Identifiers

PMID24795811
PMCPMC4007165
OpenAlexW2040528896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.